BRPI1009860A8 - composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais - Google Patents

composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais Download PDF

Info

Publication number
BRPI1009860A8
BRPI1009860A8 BRPI1009860A BRPI1009860A BRPI1009860A8 BR PI1009860 A8 BRPI1009860 A8 BR PI1009860A8 BR PI1009860 A BRPI1009860 A BR PI1009860A BR PI1009860 A BRPI1009860 A BR PI1009860A BR PI1009860 A8 BRPI1009860 A8 BR PI1009860A8
Authority
BR
Brazil
Prior art keywords
diseases
prevention
compound
humans
animals
Prior art date
Application number
BRPI1009860A
Other languages
English (en)
Portuguese (pt)
Inventor
Marcilla Etxenike Amaia
Horacio López Daniel
Barceló Coblijn Gwendolyn
Laura Martín María
Higuera Urbano Mónica
Vicente Escribá Ruiz Pablo
Álvarez Martínez Rafael
Terés Jiménez Silvia
Lladó Cañellas Victoria
Busquets Xaubet Xavier
Original Assignee
Lipopharma Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopharma Therapeutics S L filed Critical Lipopharma Therapeutics S L
Publication of BRPI1009860A2 publication Critical patent/BRPI1009860A2/pt
Publication of BRPI1009860A8 publication Critical patent/BRPI1009860A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI1009860A 2009-03-16 2010-03-15 composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais BRPI1009860A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200900725A ES2345241B1 (es) 2009-03-16 2009-03-16 Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
PCT/ES2010/070153 WO2010106211A1 (es) 2009-03-16 2010-03-15 Uso de derivados de ácidos grasos poliinsaturados como medicamentos

Publications (2)

Publication Number Publication Date
BRPI1009860A2 BRPI1009860A2 (pt) 2016-03-08
BRPI1009860A8 true BRPI1009860A8 (pt) 2019-12-17

Family

ID=42673244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009860A BRPI1009860A8 (pt) 2009-03-16 2010-03-15 composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais

Country Status (19)

Country Link
US (7) US9161928B2 (ja)
EP (2) EP2409963B1 (ja)
JP (1) JP5904592B2 (ja)
KR (4) KR20180021931A (ja)
CN (4) CN106349058B (ja)
AU (6) AU2010224749B2 (ja)
BR (1) BRPI1009860A8 (ja)
CA (1) CA2754963C (ja)
CL (1) CL2011002268A1 (ja)
DK (2) DK3159329T3 (ja)
ES (3) ES2345241B1 (ja)
HK (1) HK1232207A1 (ja)
HU (2) HUE051850T2 (ja)
MX (1) MX2011009614A (ja)
PL (1) PL2409963T3 (ja)
PT (2) PT3159329T (ja)
RU (1) RU2513995C2 (ja)
SI (1) SI3159329T1 (ja)
WO (1) WO2010106211A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドRetrotope, Inc. Pufa誘導体による酸化ストレス障害の緩和
WO2012148926A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
CA2834343C (en) 2011-04-26 2021-10-12 Retrotope, Inc. Disorders implicating pufa oxidation
JP6106158B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドRetrotope, Inc. 酸化的網膜疾患
CA2834342C (en) 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
KR101970151B1 (ko) 2014-10-21 2019-04-19 유니버시다드 데 레스 일레스 발레아르스 하이드록시-트리글리세라이드의 합성 방법 및 질병의 예방 및 치료에 사용되는 하이드록시-트리글리세라이드의 용도
EP3267200A4 (en) * 2015-03-06 2018-08-22 Niigata University Biomarker of dementia with lewy bodies
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
US11260042B2 (en) * 2017-05-16 2022-03-01 Ability Pharmaceuticals S.L. Pharmaceutical combination for the treatment of cancer
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
DK3813946T3 (da) 2018-06-15 2024-08-19 Janssen Pharmaceutica Nv Rapamycin-analoger og anvendelser deraf
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス, インコーポレイテッド ラパマイシン類似体及びその使用
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
CA3166307C (en) * 2020-01-29 2024-05-21 Pablo Vicente Escriba Ruiz Alpha-hydroxylated fatty acid metabolites, medical uses of same and use as biomarkers
BR112022014074A2 (pt) 2020-02-10 2022-09-13 Ability Pharmaceuticals S L Combinação farmacêutica para o tratamento de um câncer
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESS FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717816D0 (en) 1987-07-28 1987-09-03 Manchester Inst Science Tech Fabric testing apparatus
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) * 1991-06-21 1993-01-08 Sagami Chem Res Center ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) * 1999-06-29 2002-07-01 Consejo Superior Investigacion Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en) 2000-07-20 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) * 2001-02-12 2002-08-29 Celanese Ventures Gmbh Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
WO2003084305A2 (en) * 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
CA2607247C (en) 2005-05-04 2015-10-06 Pronova Biopharma Norge As .alpha.-substituted dha derivatives
US8059805B2 (en) * 2005-06-30 2011-11-15 Emc Corporation Enhanced services provided using communication redirection and processing
CN103211807A (zh) 2005-07-08 2013-07-24 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
JP2010508262A (ja) 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
US8399516B2 (en) * 2006-11-01 2013-03-19 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

Also Published As

Publication number Publication date
AU2020205213A1 (en) 2020-07-30
ES2820025T3 (es) 2021-04-19
MX2011009614A (es) 2012-01-20
CN106420686A (zh) 2017-02-22
AU2020205214B2 (en) 2021-02-18
US20180085332A1 (en) 2018-03-29
KR20200024953A (ko) 2020-03-09
US9763906B2 (en) 2017-09-19
BRPI1009860A2 (pt) 2016-03-08
KR102233102B1 (ko) 2021-03-26
ES2345241A1 (es) 2010-09-17
CN106349058B (zh) 2020-01-14
AU2016238970B2 (en) 2018-03-08
US9907772B2 (en) 2018-03-06
DK3159329T3 (da) 2020-11-09
US9763907B2 (en) 2017-09-19
ES2613606T3 (es) 2017-05-24
EP2409963A4 (en) 2013-10-02
CN106420686B (zh) 2020-05-22
US11253497B2 (en) 2022-02-22
CL2011002268A1 (es) 2012-01-27
AU2018203976B2 (en) 2019-06-06
PT3159329T (pt) 2020-11-13
US20170035720A1 (en) 2017-02-09
RU2513995C2 (ru) 2014-04-27
KR101833772B1 (ko) 2018-03-02
SI3159329T1 (sl) 2021-01-29
CA2754963A1 (en) 2010-09-23
HK1232207A1 (zh) 2018-01-05
AU2019226257B2 (en) 2020-05-07
JP2012520344A (ja) 2012-09-06
US20160158181A1 (en) 2016-06-09
ES2345241B1 (es) 2011-09-08
AU2018203976A1 (en) 2018-06-21
KR20190018754A (ko) 2019-02-25
US10201515B2 (en) 2019-02-12
EP2409963B1 (en) 2017-01-04
AU2020205214A1 (en) 2020-07-30
CA2754963C (en) 2022-02-08
AU2019226257A1 (en) 2019-09-26
AU2020205213B2 (en) 2021-02-25
EP2409963A1 (en) 2012-01-25
KR20180021931A (ko) 2018-03-05
WO2010106211A1 (es) 2010-09-23
DK2409963T3 (en) 2017-02-27
US20200352891A1 (en) 2020-11-12
AU2010224749A1 (en) 2011-10-13
HUE051850T2 (hu) 2021-03-29
RU2011141850A (ru) 2013-04-27
CN109999018A (zh) 2019-07-12
EP3159329A1 (en) 2017-04-26
AU2016238970A1 (en) 2016-11-03
CN102356057A (zh) 2012-02-15
US9161928B2 (en) 2015-10-20
HUE032027T2 (en) 2017-08-28
EP3159329B1 (en) 2020-08-12
CN106349058A (zh) 2017-01-25
PT2409963T (pt) 2017-02-15
US20120108550A1 (en) 2012-05-03
US20190365690A1 (en) 2019-12-05
AU2010224749B2 (en) 2016-07-07
KR20110137365A (ko) 2011-12-22
PL2409963T3 (pl) 2017-05-31
JP5904592B2 (ja) 2016-04-13
US20160158180A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
BRPI1009860A8 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
BR112015009975A2 (pt) métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal
BR112017017840A2 (pt) composição compreendendo sialil-lactose para uso na melhora das capacidades de aprendizado e função de memória
BR112015018479A2 (pt) composições nutricionais contendo glóbulos de gordura estruturados e seus usos
BR112015018411A2 (pt) composições nutritivas contendo uma fração lipídica enriquecida e usos destas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112013018539A2 (pt) Novas fucosil transferases e suas aplicações
BR112014008511A2 (pt) composições nutricionais com fitonutrientes
BR112015022936A2 (pt) vesículas de colestossoma para a incorporação de moléculas em quilomícrons
BR112013026661A2 (pt) método de entrega de vacina
BR112016010803B8 (pt) Suplemento alimentar a base de ácido resínico e uso não terapêutico de um suplemento alimentar a base de ácido resínico
BR112017009678A2 (pt) composição optimizada de nutrientes de ácidos graxos e método de preparação da mesma
BR112014001291A2 (pt) dispositivos médicos com garras giratórias destacáveis
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BR112014012808A2 (pt) proteína de fusão anticâncer
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
BR112014019927A8 (pt) fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente
BR112018000214A2 (pt) composições nutricionais e métodos para promoção de desenvolvimento cognitivo
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112012000115B8 (pt) composição compreendendo aminoácidos e/ou peptídeos bioativos e óleo marinho em uma emulsão óleo-em-água estável, processo para a produção e seus usos
BR112014008512A2 (pt) composições nutricionais de caseína-soro de leite parcialmente hidrolizadas para redução do início de alergias
BR112015032572A2 (pt) composições e métodos para melhorar o desempenho durante exercícios
BR112017006416A2 (pt) composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico
BR112021026374A2 (pt) Composição de cbd
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]